Han Z C, Maurer A M, Bellucci S, Wan H Y, Kroviarski Y, Bertrand O, Caen J P
Institut des Vaisseaux et du Sang, INSERM U 160, Paris, France.
J Lab Clin Med. 1992 Oct;120(4):645-60.
The effect of platelet factor 4 (PF4) on the growth of human erythroleukemia cell line (HEL) and the binding characteristics of iodine 125-labeled PF4 to cells were studied to determine the mechanism of action of PF4. HEL cells were cocultured with various doses of PF4 in either a plasma clot system for colony assay or a liquid system for tritiated thymidine incorporation. A significant inhibition of HEL colony growth and tritiated thymidine incorporation was seen at PF4 doses of 1 microgram/ml and 0.5 microgram/ml, respectively. The inhibitory effect of PF4 could be abrogated by the addition of heparin (5 to 10 micrograms/ml). Enzyme-linked immunosorbent assay showed that PF4 had no obvious effect on the expression of platelet glycoprotein IIb/IIIa of HEL cells. Binding of 125I-PF4 to HEL cells reached equilibrium within 20 to 30 minutes with dissociation constant of 1.3 x 10(-10)M and Bmax of 6.3 pmol/10(5) cells and was inhibited by an excess of unlabeled PF4, beta TG, and heparin but was not affected by PMA, IL-3, IL-6, GM-CSF, and interferon-alpha. PF4 did not affect the binding of 125I-IL-3 and 125I-IL-6 to HEL cells. These data demonstrate that PF4 inhibits the growth of HEL cells by specific binding to HEL cells and suggest that the action of PF4 may be associated with the heparin-binding sites of the molecule.
研究了血小板因子4(PF4)对人红白血病细胞系(HEL)生长的影响以及125碘标记的PF4与细胞的结合特性,以确定PF4的作用机制。在用于集落测定的血浆凝块系统或用于氚标记胸腺嘧啶核苷掺入的液体系统中,将HEL细胞与不同剂量的PF4共培养。在PF4剂量分别为1微克/毫升和0.5微克/毫升时,观察到HEL集落生长和氚标记胸腺嘧啶核苷掺入受到显著抑制。添加肝素(5至10微克/毫升)可消除PF4的抑制作用。酶联免疫吸附测定表明,PF4对HEL细胞血小板糖蛋白IIb/IIIa的表达没有明显影响。125I-PF4与HEL细胞的结合在20至30分钟内达到平衡,解离常数为1.3×10(-10)M,Bmax为6.3皮摩尔/10(5)个细胞,并且受到过量未标记的PF4、βTG和肝素的抑制,但不受佛波酯、白细胞介素-3、白细胞介素-6、粒细胞-巨噬细胞集落刺激因子和干扰素-α的影响。PF4不影响125I-白细胞介素-3和125I-白细胞介素-6与HEL细胞的结合。这些数据表明,PF4通过与HEL细胞特异性结合来抑制HEL细胞的生长,并提示PF4的作用可能与该分子的肝素结合位点有关。